Skip to content

PK Intravenous Lidocaine Infusion

Pharmacokinetics of Intravenous Lidocaine Infusion in Children

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02241096
Enrollment
2
Registered
2014-09-16
Start date
2015-01-31
Completion date
2015-09-30
Last updated
2020-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Surgery

Brief summary

To determine safe concentration level of lidocaine infusion in children.

Detailed description

This study will address the working hypothesis that intravenous lidocaine may be administered as a bolus followed by an infusion with reliable and safe blood levels of lidocaine. Serial blood draws will be obtained to determine safety of lidocaine doses used in this study by measuring blood levels of lidocaine and its metabolites.

Interventions

DRUGLidocaine

IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 15 Years
Healthy volunteers
No

Inclusion criteria

* male or female children 3-15 years of age * ASA physical status 1-3 * scheduled for colorectal surgery with abdominal incision

Exclusion criteria

* ASA physical status \> 3 * postoperative intubation planned ahead of surgery * history of chronic use of opioid (use longer than 3 months) * history of hepatic, renal, or cardiac failure * history of significant liver disease including liver failure, acute or chronic hepatitis, hepatomegaly, portal hypertension and elevated liver enzymes * history of organ transplant * BMI \> 30 * history of cardiac arrhythmia * history of long QT syndrome * history of allergic reaction to lidocaine or similar agents * history of seizure disorder * patient without PICC or other central access with contraindication to inhalation induction * family history or known patient susceptibility to malignant hyperthermia

Design outcomes

Primary

MeasureTime frameDescription
Safe serum levels of lidocaine infusion (<5 mcg/ml of lidocaine in blood)Samples will be collected until the end of the OR case and up to 24 hours after surgeryBlood samples will be obtained at predetermined times after start and finish of lidocaine infusion. Each sample is 1ml. Samples will be obtained at the baseline placement of IV, 0 - 3 minutes after bolus has completed, 9 - 15 minutes after bolus infusion, 4 minutes prior to end or at the end of the continuous infusion, 55 - 65 following the end of infusion, 2 - 7 hours after completion of continuous infusion and 20 - 24 hours after completion of infusion if clinical labs are also necessary.

Secondary

MeasureTime frameDescription
Safe metabolite levels (monoethylglycinexylidide (MEGX) and glycinexylidide (GX) with intraoperative IV lidocaine infusionsSamples will be collected until the end of the OR case and up to 24 hours after surgeryWe will monitor monoethylglycinexylidide (MEGX) and glycinexylidide (GX). Blood samples (1ml each) for metabolites will be as follows: baseline with initial placement, 4 minutes after infusion completed, 2 - 7 hours after infusion completion, 20 - 24 hours after infusion completion if clinical labs are being drawn

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026